Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484
Debt
Debt-to-Equity Ratio0.11
Current Ratio1.94
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio46.89
Forward P/E Ratio74.25
P/E Growth3.24
Sales & Book Value
Annual Sales$240.18 million
Price / Sales3.43
Cash Flow$0.7525 per share
Price / Cash23.68
Book Value$7.34 per share
Price / Book2.43
Profitability
EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-3.39%
Return on Equity2.15%
Return on Assets1.57%
Miscellaneous
Employees1,644
Outstanding Shares46,260,000
Market Cap$801.16 million
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share buyback plan on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, August, 8th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.05. The business had revenue of $71 million for the quarter, compared to analysts' expectations of $64.22 million. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The business's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 EPS. View Amphastar Pharmaceuticals' Earnings History.
When is Amphastar Pharmaceuticals' next earnings date?
What price target have analysts set for AMPH?
6 brokerages have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their predictions range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $20.80 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.
What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT) and Myokardia (MYOK).
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 68)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 71)
- Mr. Jason B. Shandell, Pres & Director (Age 44)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
- Mr. Rong Zhou, Exec. VP of Production Center (Age 59)
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
News headlines about AMPH stock have been trending positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.28 on Accern's scale. They also assigned media headlines about the company an impact score of 48.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Amphastar Pharmaceuticals.
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.27%), Dimensional Fund Advisors LP (3.80%), Federated Investors Inc. PA (2.74%), Bank of New York Mellon Corp (0.88%), Cortina Asset Management LLC (0.84%) and Rothschild Asset Management Inc. (0.71%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which institutional investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Fisher Asset Management LLC, Russell Investments Group Ltd., Voya Investment Management LLC, BlueMountain Capital Management LLC, Bank of New York Mellon Corp, Bank of America Corp DE and Millennium Management LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which institutional investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Investors Inc. PA, Cortina Asset Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, GSA Capital Partners LLP, Engineers Gate Manager LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $17.82.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $801.16 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
